Irinox 20 mg/ml (IV Infusion)
40 mg vial: ৳ 2,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Irinotecan hydrochloride |
| Company | Beacon pharmaceuticals plc |
Indications
- Component of first-line therapy for metastatic carcinoma of the colon or rectum
- For patients with recurrent or progressed disease following initial Fluorouracil-based therapy
Pharmacology
- Derivative of Camptothecin
- Interacts with topoisomerase I
- Prevents religation of DNA single-strand breaks
Dosage & Administration
- Different dosage regimens for colorectal cancer combination and single agent therapy
- Intravenous infusion over 90 minutes
- Intravenous bolus infusion
- Intravenous infusion over 22 hours
Interaction
- Risks of dehydration with diuretics
- Enhanced lymphocytopenia with prophylactic dexamethasone
- Increased incidence of akathisia with prochlorperazine
- Reduced exposure with St John's wort and ketoconazole
Contraindications
- Hypersensitivity to the drug or its excipients
Side Effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Constipation
- Anorexia
- Mucositis
- Neutropenia
- Leukopenia
- Anemia
- Thrombocytopenia
- Asthenia
- Pain
- Fever
- Infection
- Abnormal bilirubin
- Alopecia
Pregnancy & Lactation
- Pregnancy category D
- Can cause fetal harm
- Excretion in human milk not known
Precautions & Warnings
- Early and late diarrhea
- Cholinergic symptoms
- Bradycardia
- Myelosuppression
- Deaths due to sepsis
- Febrile neutropenia
- Increased risk for neutropenia in individuals with reduced UGT1A1 activity
Use in Special Populations
- Effectiveness in pediatric patients not established
- Greater risk of early and late diarrhea in geriatric patients
- No evaluation in patients with renal impairment
- Diminished clearance in patients with hepatic impairment
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store at controlled room temperature 15° to 30°C
- Protect from light
- Keep the vial in the carton until the time of use